SEC Filing Summary: AspenBio Pharma, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by AspenBio Pharma, Inc. on November 27, 2007. The registrant is a Colorado-based company (Commission File Number 0-50019) focused on medical diagnostics. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific corporate event rather than a financial statement.
Material Changes and Events
- Regulation FD Disclosure (Item 7.01): On November 27, 2007, the company issued a press release confirming it is pursuing the FDA 510(k) application pathway for an appendicitis blood test.
- Exhibits (Item 9.01): The press release titled "AspenBio Pharma - Confirms it is Pursuing FDA 510(k) Application Pathway for Appendicitis Blood Test" is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks beyond the regulatory context of the FDA 510(k) pathway. The primary focus is the confirmation of the regulatory strategy for the appendicitis blood test.
Investor Verification Checklist
- Verify the status of the FDA 510(k) application for the appendicitis blood test.
- Confirm the timeline for potential FDA approval or clearance.
- Review subsequent filings for updates on the regulatory pathway or clinical trial results.
- Check for any financial impact disclosures related to the development of this test in future quarterly reports.